17 completed, 4 terminated, 2 unknown, 1 active not recruiting. 11 Phase 3, 9 Phase 2, 5 Not applicable, 1 Early Phase 1, 1 Phase 4.
Follow Paromomycin: new trials by email Literature Review of Paromomycin trials Research Report on Paromomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin - Cutaneous Leihmaniasis | Phase 3 | Not yet recruiting | Institute of Tropical Medicine, Belgium | 900 | 2027-01-01 | 2026-03-10 |
| LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study LXE408, sodium stibogluconate, Paromomycin - Primary Visceral Leishmaniasis | Phase 2 | Completed | Drugs for Neglected Diseases | 52 | 2024-03-29 | 2025-12-18 |
| Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults Paromomycin - Dientamoeba Fragilis Infection | Not applicable | Recruiting | Sheba Medical Center | 60 | 2024-01-22 | 2025-04-02 |
| A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis Sodium stibogluconate / paramomycin - Visceral Leishmaniasis | Active not recruiting | University of York | 216 | 2022-05-22 | 2025-07-24 | |
| Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Miltefosine and Paromomycin, miltefosine, paromomycin - Cutaneous Leishmaniasis, American | Phase 2 / Phase 3 | Completed | Fundacion Nacional de Dermatologia | 120 | 2019-02-01 | 2021-02-02 |
| Short Course Regimens for Treatment of PKDL (Sudan) Paromomycin, Ambisome, Miltefosine - PKDL - Post-Kala-Azar Dermal Leishmanioid | Phase 2 | Unknown | Drugs for Neglected Diseases | 110 | 2018-05-09 | 2020-01-18 |
| Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Miltefosine, Paromomycin, Sodium stibogluconate - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 439 | 2018-01-24 | 2024-02-29 |
| Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Paromomycin Sulfate, Pentamidine Isethionate, Placebo - Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex | Phase 2 / Phase 3 | Completed | Fundacion Nacional de Dermatologia | 80 | 2017-04-15 | 2021-02-02 |
| Patients Response to Early Switch To Oral:Osteomyelitis Study oral antibiotics, intravenous antibiotics - Osteomyelitis | Early Phase 1 | Terminated | Julio Ramirez | 11 | 2014-03-06 | 2021-04-06 |
| Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis WR 279,396 - Leishmaniasis, Cutaneous | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 1 | 2013-09-01 | 2019-11-22 |
| Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama WR 279,396, Paromomycin - Cutaneous Leishmaniasis | Phase 3 | Completed | U.S. Army Medical Research and Development Command | 399 | 2013-05-01 | 2018-02-14 |
| The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit Paromomycin Sulfate Fasted State, Paromomycin Sulfate Fed State, Paromomycin Sulfate w/ domperidone - Concentration-Time Profiles in Stomach & Intestine. | Not applicable | Unknown | KU Leuven | 10 | 2013-02-01 | 2014-01-29 |
| WR 279,396 Open Label Treatment Protocol in Tunisia WR 279,396 topical cream - Cutaneous Leishmaniasis | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 50 | 2011-12-01 | 2014-12-19 |
| An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Paromomycin sulfate - Visceral Leishmaniasis | Not applicable | Completed | PATH | 120 | 2011-01-01 | 2014-04-04 |
| Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Liposomal amphotericin B, liposomal amphotericin B + miltefosine, liposomal amphotericin B + paromomycin - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 602 | 2010-05-01 | 2016-01-21 |
| Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream), Paromomycin Alone Cream (15% paromomycin topical cream) - Leishmaniasis, Cutaneous | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 30 | 2010-03-01 | 2015-07-16 |
| Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream), Paromomycin Alone Cream (15% paromomycin topical cream) - Leishmaniasis, Cutaneous | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 30 | 2010-01-01 | 2015-07-16 |
| Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Amphotericin B Deoxycholate, Ambisome + Miltefosine, Ambisome and Paromomycin - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 634 | 2008-06-01 | 2010-02-11 |
| An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Paromomycin - Visceral Leishmaniasis | Phase 3 | Completed | Banaras Hindu University | 329 | 2008-02-01 | 2008-09-12 |
| Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Paromomycin sulfate - Visceral Leishmaniasis | Phase 4 | Completed | PATH | 2000 | 2007-10-01 | 2014-10-03 |
Showing 20 of 27. Sign in to see all of them.
Leishmaniasis, Visceral (10) · Leishmaniasis, Cutaneous (8) · Leishmaniasis (5) · Acquired Immunodeficiency Syndrome (2) · Cryptosporidiosis (2) · HIV Infections (2) · Leishmaniasis, Mucocutaneous (2) · AIDS-Related Opportunistic Infections (1) · Bacterial Infections (1) · Communicable Diseases (1) · Diarrhea (1) · Dientamoebiasis (1) · Drug-Related Side Effects and Adverse Reactions (1) · Immune System Diseases (1) · Medication Adherence (1)
Drugs for Neglected Diseases (6) · U.S. Army Medical Research and Development Command (6) · PATH (3) · Banaras Hindu University (2) · Fundacion Nacional de Dermatologia (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · FDA Office of Orphan Products Development (1) · Institute of Tropical Medicine, Belgium (1) · Julio Ramirez (1) · KU Leuven (1) · Sheba Medical Center (1) · University of York (1)
India (5) · United States (5) · Ethiopia (4) · Kenya (3) · Sudan (3) · Bangladesh (2) · Bolivia (2) · Panama (2) · Uganda (2) · Belgium (1) · Israel (1) · Peru (1) · Puerto Rico (1) · Tunisia (1)
Shyam Sundar, MD (3) · P K Sinha, MD (2) · A. Clinton White (1) · Afif Ben Salah, M.D., Ph.D. (1) · Ahmed M Musa, MD, Prof (1) · Alejandro Llanos-Cuentas, M.D. (1) · Amrendra K Aditya, MD (1) · C P Thakur, MD (1) · Carey J (1) · Dafna Yahav, MD (1) · David Seligson, MD (1) · Devendra Nath, MD (1) · Dr. S.K. Bhattacharya (1) · Farrokh Modabber (1)
PMID 23877689, PMID 15276398, PMID 15840453, PMID 17582067, PMID 19588358, PMID 19663597, PMID 21049063, PMID 21255828, PMID 22530208, PMID 22724029, PMID 26496648, PMID 28558062, PMID 30260376, PMID 36164254, PMID 37988402, PMID 39007942, PMID 4902833, PMID 8948280